Puma Biotechnology, Inc. (PBYI) is a publicly traded biopharmaceutical company that specializes in developing and commercializing innovative novel therapeutics for the treatment of cancer. Founded in 2010 by Alan H. Auerbach, a seasoned professional with significant industry experience in oncology drug development, Puma Biotechnology is headquartered in Los Angeles, California.
Puma Biotechnology mirrors its founder’s vision of leveraging science and innovation to advance cancer treatment. Its lead drug product is Nerlynx (neratinib), an oral tyrosine kinase inhibitor that targets the human epideral growth factor receptor 2 (HER2) protein. Approved by the U.S Food and Drug Administration (FDA) in 2017, Nerlynx is primarily used as an extended adjuvant treatment for adult patients with early-stage HER2 overexpressed/amplified breast cancer.
What sets Puma Biotechnology apart in the pharmaceutical industry is its purely focused commitment to cancer therapies, specifically targeting HER2+ breast cancer. This condition affects approximately 20% of all breast cancer patients worldwide and Puma's dedicated research and development strategies signify an important contribution to addressing the unmet medical needs of these patients.
This research-driven company is actively involved in several clinical trials aimed at expanding the therapeutic indications of Nerlynx, not only within the breast cancer space but also for other types of cancers that overexpress or have a mutation in the HER2 gene. The company focuses on innovation and consistent growth all while placing value on patient safety, efficacy, and enhanced quality of life.
Moreover, Puma’s dedication to cancer care extends to practitioner education and patient assistance. It provides healthcare professionals with comprehensive resources and support tools to better understand the optimal use of its medicine. For patients, the company facilitates access to therapy through its Puma Patient Lynx program, which offers financial assistance to eligible individuals.
Despite regulatory pressures and stringent industry standards which demand constant vigilance and commitment to quality compliance, Puma Biotechnology has displayed commendable resilience and adaptability. Listed on the NASDAQ Global Select Market under the ticker symbol "PBYI", the company has demonstrated a consistent ability to successfully navigate through the complex landscape of drug development.
In conclusion, Puma Biotechnology embodies a relentless pursuit of revolutionary drug therapies to ease the burden of cancer patients worldwide. Be it through the development of therapeutic solutions, the provision of resources to enhance healthcare practices or providing financial assistance, Puma is a key player dedicated to making a significant impact in the fight against cancer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This Zacks Analyst Blog highlights four breast cancer drug stocks—AstraZeneca, Roche, Puma Biotechnology, and Olema Oncology—for Breast Cancer Awareness Month. The article details each company's breast cancer portfolio, pipeline developments, and financial performance, noting their Zacks Ranks (Hold for AstraZeneca, Puma, and Olema; Sell for Roche) and emphasizing the opportunities and risks in the breast cancer treatment landscape.
Puma Biotechnology reported Q2 2026 total revenue of $56.5 million, with NERLYNX net product revenue reaching $53.6 million. The company has raised its full-year 2026 guidance for NERLYNX product revenue to $205-$209 million and net income to $17-$20 million. Puma is also advancing its Phase 2 trials for alisertib in breast and lung cancer, with plans for potential Phase 3 trials in the future.
Alan H. Auerbach, President, CEO, and director of Puma Biotechnology, Inc., saw a warrant for 2,116,250 common shares expire unexercised on October 4, 2026. This expiration reduced his beneficial ownership in the company. Following this, Auerbach now beneficially owns 8,648,958 shares, representing approximately 16.0% of Puma Biotechnology's outstanding shares, over which he holds sole voting and dispositive power.